Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease

Human Molecular Genetics

Volumn 23, Issue 8, 2014, Pages 2030-2042

  Ribeiro, Fabiola M ^a   DeVries, Rebecca A ^b   Hamilton, Alison ^b   Guimaraes, Isabella M ^a   Cregan, Sean P ^b   Pires, Rita G W ^c   Ferguson, Stephen S G ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPHETAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DYNACTIN; DYNACTIN 3; DYNEIN ADENOSINE TRIPHOSPHATASE; DYNEIN LIGHT CHAIN 6; HUNTINGTIN; MESSENGER RNA; METABOTROPIC RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; DRUG ELIMINATION; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; HEAVY CHAIN; HUNTINGTON CHOREA; KNOCKOUT MOUSE; LOCOMOTION; MOUSE; MOUSE MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MICROARRAY; RNA TRANSCRIPTION; ROTAROD TEST; UNINDEXED SEQUENCE; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUNTINGTON DISEASE; IMMUNOENZYME TECHNIQUES; INTRANUCLEAR INCLUSION BODIES; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, METABOTROPIC GLUTAMATE 5; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THIAZOLES;

EID: 84897867203     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt598     Document Type: Article

References (44)

1. Li, S.H. and Li, X.J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. TIGS, 20, 146-154.
2. Young, A.B. (2003) Huntingtin in health and disease. J. Clin. Invest., 111, 299-302.
3. DeLong, M.R. (1990) Primate models of movement disorders of basal ganglia origin. TINS, 13, 281-285.
4. THsDCR, G. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
5. Vincent, S.R., Staines, W.A. and Fibiger, H.C. (1983) Histochemical demonstration of separate populations of somatostatin and cholinergic neurons in the rat striatum. Neurosci. Lett., 35, 111-114.
6. Ferrante, R.J., Kowall, N.W., Richardson, E.P. Jr, Bird, E.D. and Martin, J.B. (1986) Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett., 71, 283-288.
7. Ferrante, R.J., Beal, M.F., Kowall, N.W., Richardson, E.P. Jr and Martin, J.B. (1987) Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res., 411, 162-166.
8. Parent, A. (1990) Extrinsic connections of the basal ganglia. TINS, 13, 254-258.
9. Joel, D. and Weiner, I. (1994) The organization of the basal ganglia-thalamocortical circuits: open interconnected rather than closed segregated. Neurosci., 63, 363-379.
10. Smith, Y., Bevan, M.D., Shink, E. and Bolam, J.P. (1998) Microcircuitry of the direct and indirect pathways of the basal ganglia. Neurosci., 86, 353-387.
11. Galvan, A., Kuwajima, M. and Smith, Y. (2006) Glutamate and GABA receptors and transporters in the basal ganglia: what does their subsynaptic localization reveal about their function? Neurosci., 143, 351-375.
12. Gray, L., van den Buuse, M., Scarr, E., Dean, B. and Hannan, A.J. (2009) Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-Daspartic acid receptor up-regulation. Int. J. Neuropsychopharmacol., 12, 45-60.
13. McGeehan, A.J., Janak, P.H. and Olive, M.F. (2004) Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl) pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, D-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacol., 174, 266-273.
14. Rong, R., Ahn, J.Y., Huang, H., Nagata, E., Kalman, D., Kapp, J.A., Tu, J., Worley, P.F., Snyder, S.H. and Ye, K. (2003) PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat. Neurosci., 6, 1153-1161.
15. Hou, L. and Klann, E. (2004) Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci., 24, 6352-6361.
16. Mao, L., Yang, L., Tang, Q., Samdani, S., Zhang, G. and Wang, J.Q. (2005) The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J. Neurosci., 25, 2741-2752.
17. Anborgh, P.H., Godin, C., Pampillo, M., Dhami, G.K., Dale, L.B., Cregan, S.P., Truant, R. and Ferguson, S.S.G. (2005) Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin. J. Biol. Chem., 280, 34840-34848.
18. Schiefer, J., Sprunken, A., Puls, C., Luesse, H.G., Milkereit, A., Milkereit, E., Johann, V. and Kosinski, C.M. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res., 1019, 246-254.
19. Doria, J., Silva, F., de Souza, J., Vieira, L., Carvalho, T., Reis, H., Pereira, G., Dobransky, T. and Ribeiro, F. (2013) Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease. Br. J. Pharmacol., 169, 909-921.
20. Ribeiro, F.M., Paquet, M., Ferreira, L.T., Cregan, T., Swan, P., Cregan, S.P. and Ferguson, S.S.G. (2010) Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. J. Neurosci., 30, 316-324.
21. Menalled, L., El-Khodor, B.F., Patry, M., Suarez-Farinas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M. et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
22. Busse, C.S., Brodkin, J., Tattersall, D., Anderson, J.J., Warren, N., Tehrani, L., Bristow, L.J., Varney, M.A. and Cosford, N.D. (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine(MTEP)in rodent models of anxiety. Neuropsychopharmacol., 29, 1971-1979.
23. Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver, M., Li, X.J., Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet., 9, 503-513.
24. Adam, O.R. and Jankovic, J. (2008) Symptomatic treatment of Huntington disease. Neurotherapeutics, 5, 181-197.
25. Bonelli, R.M. and Hofmann, P. (2007) A systematic review of the treatment studies in Huntington's disease since 1990. Exp. Opin. Pharm., 8, 141-153.
26. Testa, C.M., Standaert, D.G., Young, A.B. and Penney, J.B. Jr. (1994) Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci., 14, 3005-3018.
27. Ribeiro, F.M., Ferreira, L.T., Paquet, M., Cregan, T., Ding, Q., Gros, R. and Ferguson, S.S.G. (2009) Phosphorylation-independent regulation of metabotropic glutamate receptor 5 desensitization and internalization by G protein-coupled receptor kinase 2 in neurons. J. Biol. Chem., 284, 23444-23453.
28. Carlsson, M. and Carlsson, A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. TIPS, 13, 272-276.
29. Carr, D.B. and Sesack, S.R. (1996) Hippocampal afferents to the rat prefrontal cortex: synaptic targets and relation to dopamine terminals. J. Comp. Neurol., 369, 1-15.
30. Scott, L. and Aperia, A. (2009) Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity. Neurosci., 158, 62-66.
31. Sesack, S.R. and Pickel, V.M. (1990) In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res., 527, 266-279.
32. Meltzer, L.T., Christoffersen, C.L. and Serpa, K.A. (1997) Modulation of dopamine neuronal activity by glutamate receptor subtypes. Neurosci. Biobehav. Rev., 21, 511-518.
33. Lin, C.H., Tallaksen-Greene, S., Chien, W.M., Cearley, J.A., Jackson, W.S., Crouse, A.B., Ren, S., Li, X.J., Albin, R.L. and Detloff, P.J. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet., 10, 137-144.
34. Cha, J.H. (2000) Transcriptional dysregulation in Huntington's disease. TIPS, 23, 387-392.
35. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. TIGS, 19, 233-238.
36. Huber, K.M., Kayser, M.S. and Bear, M.F. (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science, 288, 1254-1257.
37. Vanderklish, P.W. and Edelman, G.M. (2002) Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA., 99, 1639-1644.
38. Marco, S., Giralt, A., Petrovic, M.M., Pouladi, M.A., Martinez-Turrillas, R., Martinez-Hernandez, J., Kaltenbach, L.S., Torres-Peraza, J., Graham, R.K., Watanabe, M. et al. (2013) Suppressing aberrant GluN3A expression rescues synaptic and behavioural impairments in Huntington's disease models. Nat. Med., 19, 1030-1038.
39. Chevalier-Larsen, E. and Holzbaur, E.L. (2006) Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta., 1762, 1094-1108.
40. Ravikumar, B., Acevedo-Arozena, A., Imarisio, S., Berger, Z., Vacher, C., O'Kane, C.J., Brown, S.D. and Rubinsztein, D.C. (2005) Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat. Genet., 37, 771-776.
41. Koushika, S.P., Schaefer, A.M., Vincent, R., Willis, J.H., Bowerman, B. and Nonet, M.L. (2004) Mutations in Caenorhabditis elegans cytoplasmic dynein components reveal specificity of neuronal retrograde cargo. J. Neurosci., 24, 3907-3916.
42. Banks, G.T., Haas, M.A., Line, S., Shepherd, H.L., Alqatari, M., Stewart, S., Rishal, I., Philpott, A., Kalmar, B., Kuta, A. et al. (2011) Behavioral and other phenotypes in a cytoplasmic Dynein light intermediate chain 1 mutant mouse. J. Neurosci., 31, 5483-5494.
43. Wheeler, V.C., Auerbach, W., White, J.K., Srinidhi, J., Auerbach, A., Ryan, A., Duyao, M.P., Vrbanac, V., Weaver, M., Gusella, J.F. et al. (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet., 8, 115-122.
44. Lu, Y.M., Jia, Z., Janus, C., Henderson, J.T., Gerlai, R., Wojtowicz, J.M. and Roder, J.C. (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci., 17, 5196-5205.